Skip to main content
SpringerLink
Log in

Dabigatran etexilate: a guide to its use in the prevention of thromboembolic disorders

  • Clinical Questions and Answers on Drugs
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

References

  1. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011 Apr 5; 123(13): 1436–50

    Article  PubMed  Google Scholar 

  2. De Caterina R. The current role of anticoagulants in cardiovascular medicine. J Cardiovasc Med 2009; 10(8): 595–604

    Article  Google Scholar 

  3. Lafuente-Lafuente C, Mahé I, Extramiana F. Management of atrial fibrillation. BMJ 2010; 340(7736): 40–5

    Google Scholar 

  4. Connolly SJ, Eikelboom J, O’Donnell M, et al. Challenges of establishing new antithrombotic therapies in atrial fibrillation. Circulation 2007; 116(4): 449–55

    Article  PubMed  Google Scholar 

  5. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006 Apr; 27(8): 949–53

    Article  PubMed  Google Scholar 

  6. Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost 2005 Aug; 3(8): 1843–53

    Article  PubMed  CAS  Google Scholar 

  7. Pradaxa: summary of product characteristics. London: European Medicines Agency, 2009 Dec 15

  8. Pradaxa® (dabigatran etexilate mesylate capsules): US prescribing information. Ridgefield (CT); Boehringer Ingelheim Pharmaceuticals, Inc., 2011 Mar

  9. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47(5): 285–95

    Article  PubMed  CAS  Google Scholar 

  10. Pradax™ (dabigatran etexilate capsules): Canadian prescribing information. Burlington (ON); Boehringer Ingelheim Canada Ltd, 2010 Oct 26

  11. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010 Jun; 103(6): 1116–27

    Article  PubMed  Google Scholar 

  12. Hemoclot® thrombin inhibitors #CK002L: clotting assay for the quantitative measurement of hirudin and other direct thrombin inhibitors in plasma. Neuville-sur-Oise, France; Hyphen BioMed, 2010 Dec 17

  13. Stangier J, Wetzek K, Wienen W, et al. Measurement of the pharmacodynamic effect of dabigatran etexilate: thrombin clotting time [abstract no. PP-TH-134]. J Thromb Haemost 2009 Jul; 7 Suppl. 2

  14. Dabigatran plasma calibrator Ref A222801: calibration plasmas for the assay of dabigatran with anti-IIa method. Mason (OH); Aniara, 2010 Sep 30

  15. Liesenfeld KH, Schäfer HG, Trocóniz IF, et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006 Nov; 62(5): 527–37

    Article  PubMed  CAS  Google Scholar 

  16. van Ryn J, Seiger R, Kink-Eiband M, et al. Adsorption of dabigatran etexilate in water or dabigatran in pooled human plasma by activated charcoal in vitro [abstract no. 1065]. 51st American Society of Hematology Annual Meeting and Exposition; 2009 Dec 5–8; New Orleans (LA)

  17. Stangier J, Rathgen K, Stähle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49(4): 259–68

    Article  PubMed  CAS  Google Scholar 

  18. Eikelboom JW, Wallentin L, Yusuf S, et al. Does dabigatran improve stroke-prevention in atrial fibrillation? J Thromb Haemost 2010; 8(6): 1438–9

    Article  CAS  Google Scholar 

  19. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009; 361(12): 1139–51

    Article  PubMed  CAS  Google Scholar 

  20. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial [letter]. N Engl J Med 2010 Nov 4; 363(19): 1875–6. Plus supplementary material available from URL: http://www.nejm.org [Accessed 2010 Nov 17]

    Article  PubMed  CAS  Google Scholar 

  21. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010 Sep; 376(9745): 975–83

    Article  PubMed  CAS  Google Scholar 

  22. Healey JS, Eikelboom J, Wallentin L, et al. Effect of age and renal function on the risks of stroke and major bleeding with dabigatran compared to warfarin: an analysis from the RE-LY study [abstract no. 1078-120]. J Am Coll Cardiol 2010; 55(10 Suppl. 1): A4.E37–9

    Article  Google Scholar 

  23. Eriksson BI, Dahl OE, Rosencher N. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007 Sep 15; 370(9591): 949–56

    Article  PubMed  CAS  Google Scholar 

  24. Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*): a randomised, double-blind, non-inferiority trial. Thromb Haemost 2011 Apr 4; 105(4): 721–9

    Article  PubMed  CAS  Google Scholar 

  25. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007 Nov; 5(11): 2178–85

    Article  PubMed  CAS  Google Scholar 

  26. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm 2011 Mar; 8(3): e1–8

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dabigatran etexilate: a guide to its use in the prevention of thromboembolic disorders. Drugs Ther. Perspect 27, 1–8 (2011). https://doi.org/10.2165/11601590-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11601590-000000000-00000

Search

Navigation